Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Click here to view
Careers
Core Values
Open Positions
Employee Benefits
Clinical Trials
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
Science
Technology Platforms
Zinc Finger Platform
Delivery Platform
Modular Integrase (MINT) Platform
Therapeutic Applications
Neurology
Oncology
Presentations
Publications
Programs
Pipeline
Clinical Programs
Small Fiber Neuropathy (SFN)
Fabry Disease
Hemophilia A
Clinical Trials
Collaborations & Partners
Patients
Our Commitment
Expanded Access Policy
Bioethics
Patient Stories
Bryan – Fabry Disease
Lori – Fabry Disease
Matt – Fabry Disease
Elizabeth – Fabry Disease
Israel – Hemophilia A
Miles – Hemophilia A
Trevor – Prion Disease
Sharron – Renal Transplant
Patient Focus
Resources
Education
Organizations
Investors & Media
Overview
News Releases
Events
Presentations
ESG
About
Overview
Mission & Vision
Executive Leadership
Board of Directors
Latest News
News Releases
Events
Presentations
Contact
LinkedIn
Twitter
WORLD
Symposium
™ 2024
Clinical
WORLDSymposium 2024
Presentation: Updated results from ongoing phase 1/2 study (STAAR) for Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease
WORLDSymposium 2024
Poster: Updated results from ongoing phase 1/2 study (STAAR) for Isaralgagene civaparvovec (ST-920) gene therapy in adults with Fabry disease
WORLDSymposium 2024
Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease
Nonclinical
WORLDSymposium 2024
Presentation: A 3-month gene therapy single-dose IV administration pharmacology and safety study with isaralgagene civaparvovec (ST-920) for Fabry disease in mice
WORLDSymposium 2024
Poster: A 3-month gene therapy single-dose IV administration pharmacology and safety study with isaralgagene civaparvovec (ST-920) for Fabry disease in mice